Cambridge-based pioneer in nextgen human cell programming, has raised $50 million Series C cash in a round led by M&G ...
M&G Investments (M&G) today announces that it has led a US$50 million Series C funding round for bit.bio, the Cambridge-based biotech company pioneering next-generation human cell programming ...
A reliable supply of consistent and physiologically relevant motor neurons is fundamental to the study and screening of potential treatments for motor neuron diseases ioMotor Neurons also offer an ...
Synthego to develop multiplexed and complex genetic engineering strategies, increasing the safety and speed at which bit.bio can engineer human cells for cell therapies. bit.bio aims to leverage ...
Dr Hermann Hauser, serial entrepreneur, co-founder of Amadeus Capital Partners and founder of semiconductor company, Arm Ltd, and gene-sequencing company, Solexa / Illumina, joins as chair of the ...
BlueRock Therapeutics, a clinical-stage cell therapy company, and bit.bio, a synbio firm, signed a collaboration and option agreement for the discovery and manufacture of iPSC-derived regulatory T ...
CAMBRIDGE, England, Dec. 2, 2025 /PRNewswire/ -- bit.b io, the global leader in cell programming technology, today announces the publication of its 2025 Corporate Sustainability Report, reaffirming ...
Bit Bio, the new startup that pitches itself as the “enter button for the keyboard to the software of life,” only needed three weeks to raise its latest $41.5 million round of funding. Originally ...
The report provides evidence-based metrics aligned with the UN Sustainable Development Goals (SDGs), highlighting year-over-year improvements. It demonstrates how sustainability is integrated across ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback